A position statement on NAFLD/NASH based on the EASL 2009 special conference☆

Received 11 March 2010; accepted 2 April 2010. published online 07 May 2010.

Keywords: Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Steatosis, Fibrosis, Insulin resistance, Mortality, Guidelines, Diagnosis, Treatment

No abstract is available. To read the body of this article, please view the Full Text online.

a Université Pierre et Marie Curie Paris VI, Assistance Publique Hôpitaux de Paris, INSERM UMRS 893, France

b Centro Studi Fegato, Gastroenterologia, Distretto di Carpi, Azienda USL di Modena, Italy

c Departamento de Gastrenterologia, Unidade de Nutrição e Metabolismo, Hospital Universitário de Santa Maria, Instituto de Medicina Molecular, Lisbon, Portugal

d Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

e Alma Mater Studiorum, Unit of Metabolic Diseases and Clinical Dietetics, University of Bologna, Italy

Corresponding author. Tel.: +39 059371102; fax: +39 059851762.

☆ This position statement has been endorsed by the European Association for the Study of the Liver, and it is a summary of “NAFLD/NASH and Related Metabolic Disease” EASL Special Conference, held in Bologna, September 24–26, 2009.

PII: S0168-8278(10)00414-9

doi:10.1016/j.jhep.2010.04.008

31 of 35